-----BEGIN PRIVACY-ENHANCED MESSAGE----- Proc-Type: 2001,MIC-CLEAR Originator-Name: webmaster@www.sec.gov Originator-Key-Asymmetric: MFgwCgYEVQgBAQICAf8DSgAwRwJAW2sNKK9AVtBzYZmr6aGjlWyK3XmZv3dTINen TWSM7vrzLADbmYQaionwg5sDW3P6oaM5D3tdezXMm7z1T+B+twIDAQAB MIC-Info: RSA-MD5,RSA, CZRnpRasxT2O6U6YzVCXw49K1GppLBqlcgjsE756T5+QCJyOgCPspr2iaNfrMIn5 UjbFuJvC7XhFevsNjDSMNA== 0000950134-05-018712.txt : 20051004 0000950134-05-018712.hdr.sgml : 20051004 20051003193807 ACCESSION NUMBER: 0000950134-05-018712 CONFORMED SUBMISSION TYPE: 8-K PUBLIC DOCUMENT COUNT: 1 CONFORMED PERIOD OF REPORT: 20050928 ITEM INFORMATION: Entry into a Material Definitive Agreement FILED AS OF DATE: 20051004 DATE AS OF CHANGE: 20051003 FILER: COMPANY DATA: COMPANY CONFORMED NAME: CEPHEID CENTRAL INDEX KEY: 0001037760 STANDARD INDUSTRIAL CLASSIFICATION: LABORATORY ANALYTICAL INSTRUMENTS [3826] IRS NUMBER: 770441625 STATE OF INCORPORATION: CA FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: 8-K SEC ACT: 1934 Act SEC FILE NUMBER: 000-30755 FILM NUMBER: 051119182 BUSINESS ADDRESS: STREET 1: 1190 BORREGAS AVE CITY: SUNNYVALE STATE: CA ZIP: 94089 BUSINESS PHONE: 4085414191 MAIL ADDRESS: STREET 1: 1190 BORREGAS CITY: SUNNYVALE STATE: CA ZIP: 94089 8-K 1 f13138e8vk.htm FORM 8-K e8vk
 

 
 
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 8-K
CURRENT REPORT
Pursuant to Section 13 or 15(d) of the
Securities Exchange Act of 1934
Date of Report (Date of earliest event reported): September 28, 2005
CEPHEID
 
(Exact name of registrant as specified in its charter)
         
California   000-30755   77-0441625
(State or other
jurisdiction of
incorporation) 		  (Commission File Number)   (I.R.S. Employer
Identification No.)
             
    904 Caribbean Drive, Sunnyvale, CA   94089    
 
    (Address of principal executive offices)   (Zip Code)    
(408) 541-4191
 
(Registrant’s telephone number, including area code)
Not Applicable
 
(Former name or former address, if changed since last report)
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligations of the registrant under any of the following provisions (see General Instruction A.2 below):
o   Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
 
o   Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
 
o   Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
 
o   Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
 
 

 

 

Item 1.01. Entry into a Material Definitive Agreement.
     On September 28, 2005, Cepheid entered into a License Agreement (the “Agreement”) with Abaxis, Inc., effective as of September 30, 2005, pursuant to which Abaxis granted Cepheid a non-exclusive, worldwide, royalty-bearing license to certain Abaxis patents relating to lyophilization technology in accordance with the provisions specified in the Agreement.
     Under the Agreement and the licensed patents, and subject to certain limitations set forth therein, Cepheid will be able to make, have made, import, use, distribute and sell products for nucleic acid based amplification assays. In exchange for the license rights, Cepheid agreed to (i) make an upfront license payment to Abaxis, (ii) pay royalties during the term of the agreement and (iii) pay a yearly license maintenance fee during the term of the Agreement, which fee will be creditable against any royalties due during such calendar year. Cepheid may terminate the Agreement for any reason upon 30 days written notice to Abaxis.

 

 

SIGNATURES
     Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
         
  CEPHEID
 		  
Date: October 3, 2005  By:   /s/ John L. Bishop    
    Name:   John L. Bishop   
    Title:   Chief Executive Officer   
 

 

-----END PRIVACY-ENHANCED MESSAGE-----